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Similar plasma lipidomic profile in 
people living with HIV treated with 
a darunavir-based or an integrase 
inhibitor-based antiretroviral 
therapy
Alvaro Mena  1,2*, Elvira clavero1,3, José Luis Díaz-Díaz3 & Angeles castro1,2
Cardiovascular disease is an important cause of morbidity and mortality in people living with HIV 
(PLWH), who commonly experience lipid disturbances. The aim of this study was to determine whether 
the plasma lipidomic profile differs between PLWH receiving a darunavir-based ART and those receiving 
integrase inhibitor-based ART. This was a cross-sectional study of unselected patients for whom 
metabolomic analysis was performed using ultra-high-performance liquid chromatography coupled 
to mass spectrometry. Data for the two subgroups were compared by calculating the log2 of the fold 
change for each metabolite and then grouping these into the main lipid families. Sixty-two PLWH 
aged 49.3 ± 8.6 years (82% men) were included: 12 patients (19.4%) had hypertension, 8 (12.9%) had 
type 2 diabetes, 25 (41.0%) had dyslipidaemia and 9 (14.5%) were taking statins, without significant 
differences in all these variables between the two groups. Twenty-five (40.3%) received darunavir-based 
ART and 37 (59.7%) integrase inhibitor-based ART. Although the differences were not statistically 
significant, patients treated with darunavir-based ART had higher concentrations of total cholesterol 
(211 mg/dL vs 194 mg/dL), LDL-cholesterol (132 mg/dL vs 117 mg/dL) and triglycerides (155 mg/dL vs 
122 mg/dL), and lower HDL-cholesterol concentration (50 mg/dL vs 52 mg/dL). The main lipid families 
and metabolites differed slightly between groups (log2-fold change; P-value): ceramides (−0.07; 0.49), 
phosphatidylinositols (−0.05; 0.63), diacylglycerols (0.10; 0.64), phosphatidylethanolamines (0.03; 
0.78), triacylglycerols (0.27; 0.18) and lysophosphatidylethanolamines (0.03; 0.83). In the integrase 
inhibitor-based group, the use of tenofovir alafenamide fumarate significantly increases the majority of 
lipid fractions, when compared with tenofovir disoproxil fumarate. The lipidomic profile did not differ 
between PLWH treated with darunavir-based or integrase inhibitor-based ART. This was especially true 
for ceramides, which are involved in cardiovascular disease. Further studies are needed to study the 
impact of ART in lipidomic profile.
The incidence of cardiovascular (CV) events is increasing in people living with HIV (PLWH) for many reasons 
such as the improvement in life expectancy, chronic inflammatory status of the disease or toxicity of antiretroviral 
treatment (ART)1.
Dyslipidaemia is associated with increased risk of CV diseases in PLWH2. ART-induced dyslipidaemia is char-
acterized by a reduction in HDL-cholesterol and an increase in LDL-cholesterol, total cholesterol and triglyceride 
concentrations3,4. These parameters are incorporated in most of the equations used to estimate CV risk, even 
though these scores can underestimate the risk in PLWH5.
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Some molecular lipid species, especially ceramides, are involved in many central processes involved in the 
development of atherosclerosis and are significant predictors of CV death in HIV-uninfected patients with and 
without established CV diseases6,7. Ceramides have also been implicated in cell senescence and apoptosis8. PLWH 
exhibit several differences in the plasma lipid profile compared with healthy people not infected with HIV. These 
include increase levels of some metabolites such as diacylglycerols and reduced level of others such as sphingo-
myelin. However, little is known about the effects of ART on plasma lipidomic profile9.
Classically, protease inhibitors were associated with a worse lipid profile than are integrase inhibitors, as 
measured by the differences in the concentrations of cholesterol and triglycerides. However, these differences are 
smaller with modern protease inhibitors such as darunavir, especially when boosted with cobicistat instead of 
ritonavir10. The aim of this study was to determine whether the plasma lipidomic profiles differ between PLWH 
receiving a darunavir-based ART and those receiving an integrase inhibitor-based ART.
Patients and Methods
Ethics statement. The research protocol was conducted in accordance with the Declaration of Helsinki and 
the STROBE Statement11. It was reviewed and approved by the Regional Ethics Committee of Galicia (register 
code 2016/423). All participants provided written informed consent. A database was created, and all data were 
anonymized before analysis.
Patients. This was a cross-sectional study of consecutive PLWH who attended a mono-centric HIV unit. In 
this unit, approximately 1380 PLWH with stable ART are followed. Of them, 29% received a darunavir-based 
regimen and 43% an integrase inhibitor-based ART. Participants were included if they were being treated with 
a darunavir-based or an integrase inhibitor-based ART, for at least six months, were older than 18 years old, 
and signed the informed consent. The exclusion criteria were: pregnant women and people with an active 
AIDS-defining condition or an active cancer.
Demographic data, CV risk factors and HIV characteristics (duration of HIV infection, other coinfections, 
CD4 + T-cell count, HIV viral load and ART) were collected. Blood samples were obtained under fasting condi-
tions of at least 8 hours, processed and frozen at −80 °C. Participants were included in the study between January 
and March 2017.
Metabolomic analysis. Serum metabolic profiles were semi-quantified using ultra-high-performance liq-
uid chromatography coupled to mass spectrometry (UHPLC-MS) as described previously11. Briefly, two sep-
arate UHPLC-time of flight-MS-based platforms to analyse the methanol and chloroform–methanol serum 
extracts were used. A specific metabolite extraction procedure was performed for each platform. Identified 
ion features in the methanol-extraction platform included fatty acids, bile acids, monoacylglycerol phospho-
lipids, monoether glycerol phospholipids, and free sphingoid bases. The chloroform–methanol extraction plat-
form provided coverage over glycerolipids, cholesterol esters, sphingolipids, diacylglycerophospholipids, and 
acyl-ether-glycerophospholipids. The lipid nomenclature and classification follow the LIPID MAPS convention 
(www.lipidmaps.org). Metabolite extraction procedures, chromatographic separation conditions and mass spec-
trometric detection conditions have been detailed previously12. Metabolomics data were pre-processed using 
the TargetLynx application manager (MassLynx 4.1; Waters Corp., Milford, MA). Intra-batch (multiple inter-
nal standard response correction) and inter-batch (variable-specific inter-batch single-point external calibra-
tion using repeat extracts of a commercial serum sample) data normalization was performed as described by 
Martínez-Arranz13.
Statistics. Univariate analyses were performed on metabolomic-normalized data. For each metabolite, differ-
ences between subgroups were calculated as the base 2 logarithm of the fold-change. The bootstrapping method 
involving 1000 repetitions, each with 80% of the samples for each study group, was used to obtain a relatively 
unbiased estimate of fold changes and 95% confidence intervals. These values were accompanied by a significance 
level based on P-values obtained using Student’s t test. All calculations were performed using R statistical software 
package (v.3.4.1; https://www.R-project.org/).
Results
A total of 62 PLWH were included in the study: 25 (40.3%) were receiving a darunavir-based ART (all boosted 
with cobicistat) and 37 (59.7%) an integrase inhibitor-based ART. The number of patients included in each 
group represents in both cases just over 6% of the total of patients taking that ART. The average duration of the 
current therapy was 5 ± 3 years in the darunavir-based group and 4 ± 3 years in the integrase inhibitor-based 
(P-value = 0.90). The main characteristics of the study population are shown in Table 1. Both groups had a sim-
ilar profile for the main variables related to HIV infection. Patients in the darunavir-based group had a higher 
prevalence of dyslipidaemia and higher cholesterol and triglyceride concentrations than patients taking integrase 
inhibitor-based ART, but these differences were not significant.
The darunavir-based regimens were as follows: plus tenofovir disoproxil fumarate/emtricitabine in 10 patients, 
plus abacavir/lamivudine in five patients, dual therapy plus lamivudine in five patients and darunavir/cobicistat 
monotherapy in five patients.
The integrase inhibitor-based regimens were as follows: tenofovir alafenamide fumarate/emtricitabine/
elvitegravir/cobicistat in 10 patients, tenofovir disoproxil fumarate/emtricitabine/elvitegravir/cobicistat in seven 
patients, abacavir/lamivudine/dolutegravir in 18 patients and tenofovir disoproxil fumarate/emtricitabine plus 
raltegravir in two patients.
All lipid panels were compared between patients receiving darunavir-based therapy vs integrase 
inhibitor-based ART. The main lipid families and metabolites differed slightly between groups (log2-fold 
change; P-value): ceramides (−0.07; 0.49), phosphatidylinositols (−0.05; 0.63), diacylglycerols (0.10; 0.64), 
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phosphatidylethanolamines (0.03; 0.78), triacylglycerols (0.27; 0.18) and lysophosphatidylethanolamines (0.03; 
0.83). To compare the results visually, log2-fold changes and significance levels were used to create detailed heat-
maps. Supplementary Table S1 shows the data grouped according to lipid families and Table S2 shows all metab-










Male (%) 51 (82.2) 23 (92.0) 28 (75.7) 0.099
Age (years) 49.3 ± 8.6 49.1 ± 7.6 49.5 ± 9.2 0.877
Current smoker (%) 38 (61.3) 15 (60.0) 23 (63.9) 0.696
BMI (Kg/m2) 25.3 ± 4.5 26.0 ± 5.4 24.8 ± 3.7 0.327
Hypertension (%) 12 (19.4) 6 (24.0) 6 (16.2) 0.447
Type 2 Diabetes (%) 8 (12.9) 3 (12.0) 5 (13.5) 0.862
Dyslipidemia (%) 25 (41.0) 13 (52.0) 12 (33.3) 0.145
Combined dyslipidemia (%) 12 (19.4) 6 (24.0) 6 (16.2) 0.447
Current statin treatment (%) 9 (14.5) 4 (16.0) 5 (13.5) 0.785
CV risk§: 0.719
Low (<5%) 24 (38.7) 9 (36.0) 15 (40.6)
Moderate (5–10%) 25 (40.3) 11 (44.0) 14 (37.8)
High (>10%) 13 (21.0) 5 (20.0) 8 (21.6)
History of CV event 5 (8.1) 2 (8.0) 3 (8.1) 0.988
Total cholesterol (mg/dL) 201 ± 38 211 ± 36 194 ± 38 0.079
LDL cholesterol (mg/dL) 123 ± 35 132 ± 35 117 ± 34 0.100
HDL cholesterol (mg/dL) 51 ± 14 50 ± 15 52 ± 12 0.693
TG (mg/dL) 136 ± 73 155 ± 78 122 ± 67 0.095
ApoA-I (mg/dL) 188 ± 40 183 ± 43 193 ± 39 0.473
ApoB (mg/dL) 128 ± 31 132 ± 30 125 ± 33 0.539
Years since HIV infection 14 ± 8 15 ± 9 14 ± 8 0.570
Years on ART 12 ± 5 13 ± 6 12 ± 5 0.753
CDC-C category (%) 23 (37.1) 9 (36.0) 14 (37.8) 0.883
CD4 Count (cells/µL) 622 ± 296 608 ± 317 631 ± 286 0.770
Viral load <20 copies/mL (%) 58 (93.5) 23 (92.0) 35 (94.6) 0.683
RNA-HCV positive (%) 10 (16.1) 4 (16.0) 6 (16.2) 0.981
Table 1. Baseline characteristics of study participants comparing the two study groups and the P-value for 
the comparison. DRV, darunavir; INI, integrase inhibitor; BMI, body mass index; TG, triglycerides; Apo, 
apolipoprotein; CV, cardiovascular; CDC, Centers for Disease Control and Prevention; HCV, hepatitis C virus.  
§Ten-year CV risk calculated with Framingham Risk Score.
Figure 1. Base 2 logarithm of the fold-change (bootstrap, resampling method) and their 95% confidence 
interval for the comparisons between patients receiving a darunavir-based treatment and those with an 
integrase inhibitor-based. P-values obtained using Student’s t, in all cases P-value > 0.10. Cer, ceramide.
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The data of the main metabolites grouped according to the backbone in each of the two study groups are 
included and compared in Table 2. In the integrase inhibitor-based group, the use of tenofovir alafenamide fuma-
rate significantly increases the majority of lipid fractions, when compared with tenofovir disoproxil fumarate.
Discussion
In this study, we observed similar plasma lipidomic profiles in PLWH treated with darunavir/cobicistat as in those 
receiving an integrase inhibitor-based ART. To our knowledge, this study is the first to investigate the effects of 
these treatments on dyslipidaemia by analysing more than 300 metabolites.
HIV infection causes substantial inflammatory dysregulation that affects lipid metabolism and causes both 
qualitative and quantitative changes in several metabolites. Ceramides are associated with lipoprotein aggre-
gation, inflammation, reactive oxygen species production and apoptosis, and seem to be an intermediate link 
between over-nutrition and some abnormalities related to CV risk such as insulin resistance and metabolic syn-
drome10,14,15. Few studies have analysed the influence of HIV infection and ART on these metabolic pathways in 
PLWH9, but these preliminary data show a worsening of the lipid profile with the start of ART, especially with 
some drugs as efavirenz, in a recently published study16. Ceramides are not associated with HIV infection per 
se, but the levels of some metabolites of ceramide, such as dihexosylceramide or GM3, have been found to be 
decreased secondarily to HIV infection, which suggests possible dysregulation of the enzyme ceramide gluco-
syltransferase9. Wong et al. reported that ceramides strongly predicted CV events (OR 3.44) in asymptomatic 
PLWH; this finding is consistent with data from studies is in HIV-uninfected people6,7,9. These data suggest a 
potential use of plasma ceramides as markers of CV risk. Measurement of ceramide level may be of particular 
interest in PLWH, whose CV risk scores based on traditional markers underestimate their risk.
Elevated cholesterol and triglyceride levels play an unquestionable role in CV disease. However, even after 
controlling these levels, there remains a residual risk that other mediators cannot change. Most of the ARTs 
currently used in developed countries have a minor effect on cholesterol fractions and triglycerides, but fur-
ther data are needed on the entire plasma lipidomic profile to provide complete information. Darunavir/cobi-
cistat increases cholesterol and triglyceride levels in both treatment-naive and pretreated PLWH above those 
observed with an integrase inhibitor-based regimen; these differences are usually statistically significant but 
clinically have little relevance18. In this study, we found no differences in the levels of ceramides or other fam-
ilies that can affect CV risk, such as phosphatidylethanolamines, phosphatidylinositols, cholesteryl esters or 
diacylglycerols. In the study by Wong et al., all of these lipid families were associated with future CV events 
in PLWH (ORs 3 to 6)9. Recently, an interesting study has analysed the role of ceramides in the progression 
of the carotid artery atherosclerosis in PLWH. Zhao et al. communicated a good correlation between plasma 
levels of C16:0 and C24:1 ceramides and immune activation and inflammation. In their data, elevated ceramide 
levels were associated with antiretroviral therapy use, particularly with the PIs use. We do not find differences 
in ceramides between the darunavir/cobicistat-based and the integrase inhibitor-based groups. Probably, in 
the study of Zhao, there were patients taking PIs older than darunavir/cobicistat, which are already known to 
have a worse lipid profile17.
Darunavir-based (N = 25) Integrase inhibitor-based (N = 37)
ABC/3TC N = 5 TDF/FTC N = 10 Mono/dual N = 10 ABC/3TC N = 18 TDF/FTC N = 9 TAF/FTC N = 10
Ceramides 16.33 ± 6.32 14.91 ± 3.04 15.02 ± 3.21 15.10 ± 5.29 14.68 ± 3.77 19.57 ± 4.02*
Cer(d18:1/16:0) 1.64 ± 0.39 1.32 ± 0.37 1.25 ± 0.30 1.33 ± 0.34 1.23 ± 0.21 1.35 ± 0.26
Cer(d18:1/18:0) 1.72 ± 0.64 1.47 ± 0.42 1.58 ± 0.56 1.51 ± 0.53 1.32 ± 0.33 1.65 ± 0.68
Cer(d18:1/20:0) 1.63 ± 0.59 1.29 ± 0.47 1.33 ± 0.50 1.37 ± 0.53 1.36 ± 0.29 1.97 ± 0.59*
Cer(d18:1/21:0) 1.21 ± 0.44 0.98 ± 0.24 0.95 ± 0.26 1.10 ± 0.61 1.21 ± 0.49 1.69 ± 0.54
Cer(d18:1/22:0) 1.20 ± 0.39 1.08 ± 0.31 1.11 ± 0.29 1.11 ± 0.49 1.04 ± 0.32 1.64 ± 0.57*
Cer(d18:1/24:0) 1.26 ± 0.41 1.21 ± 38 1.20 ± 0.31 1.18 ± 0.53 1.18 ± 0.36 1.74 ± 0.58*
Cer(d18:1/24:1) 1.56 ± 0.32 1.50 ± 0.42 1.49 ± 0.43 1.45 ± 0.50 1.36 ± 0.34 1.80 ± 0.35*
Cer(d18:1/25:0) 1.37 ± 0.42 1.31 ± 0.38 1.28 ± 0.42 1.37 ± 0.52 1.24 ± 0.43 1.64 ± 0.56
Phosphatidylethanolamines 37.34 ± 12.49 32.26 ± 8,84 35.10 ± 8.62 35.13 ± 10.75 29.42 ± 9.18 38.24 ± 12.5
Lysophosphatidylethanolamines 22.12 ± 9.95 19.75 ± 4.12 21.71 ± 4.76 23.88 ± 7.45* 17.02 ± 4.87 23.11 ± 5.83*
Phosphatidylinositols 5.92 ± 1.84 5.90 ± 1.76 4.88 ± 0.96 6.00 ± 1.70 4.73 ± 1.70 6.51 ± 1.72*
Diacylglycerols 7.63 ± 4.91 6.48 ± 2.12 6.39 ± 1.64 7.21 ± 4.97 5.08 ± 1.77 8.64 ± 4.13*
Triacylglycerols 198.12 ± 51.18 158.26 ± 41.50 163.19 ± 40.14 179.77 ± 44.35* 148.64 ± 47.95 204.86 ± 94.87*
Cholesteryl Esters 21.84 ± 10.12 20.76 ± 5.26 18.22 ± 3.48 17.76 ± 6.32 17.33 ± 2.40 18.98 ± 5.24
Table 2. Mean and standard deviation of the main metabolites. Patients of the two study groups have been 
grouped according to the backbone. In each study group, data have been compared between different backbones 
using the tenofovir disoproxil fumarate/emtricitabine group as a reference. ABC/3TC, abacavir/lamivudine; 
TDF/FTC, tenofovir disoproxil fumarate/emtricitabine; Mono/dual, monotherapy or dual therapy (plus 
lamivudine); TAF/FTC, tenofovir alafenamide fumarate/emtricitabine; Cer, ceramide. P-value < 0.05 have been 
represented as. *All significant P-values were >0.01.
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Tenofovir disoproxil fumarate has some lipid-lowering properties, which are lost when tenofovir alafenamide 
fumarate is used; this has been shown by measuring fractions of cholesterol and triglycerides. In our data, despite 
the limitation of the sample size, patients taking tenofovir alafenamide fumarate (in all cases with an integrase 
inhibitor) had a worse lipid profile, when compared with tenofovir disoproxil fumarate and quantitatively worse 
than those who take a darunavir-based treatment, in the mail lipid metabolites. We hypothesized that, perhaps in 
the future, the backbone therapy is as important (or more) than the third agent, in the development of metabolic 
disturbances. Further studies must focus in this issue.
Lipid-lowering therapies seem to have a beneficial effect on the global lipid composition, although few studies 
have reported this finding19,20. Dietary interventions, specifically the Mediterranean diet, are effective in mitigat-
ing the deleterious effects of ceramides on CV risk, as shown by a recent report from the PREDIMED Trial7. In 
our study, few patients were taking statins (14.5%), despite the higher prevalence of dyslipidaemia (41%). This 
under-treatment of dyslipidaemia in these PLWH has been noted previously and seems to be explained by the low 
prescription rate and low adherence to lipid-lowering drugs21. Some investigators have hypothesized that statins 
are beneficial in PLWH with elevated CV risk regardless of their cholesterol levels. More studies of the levels of 
ceramides and other proatherogenic metabolites in PLWH will help to answer this question. The role of dietary 
interventions is especially interesting in PLWH and should be examined in future studies.
There are some limitations to this study. First, the small sample size limited the statistical power and did not 
allow us to analyse the interactions of different variables, especially the role of the different backbone therapies. 
Even though the groups were homogeneous, some bias was possible. This study has been designed as a proof of 
concept, so a sample size calculation has not been performed. The low proportion of women (<20%) limits the 
validity of our findings for women, and further studies are required. It was not possible to analyse specifically the 
role of lipid-lowering therapies in PLWH, and dietary data were not collected. The inclusion of a HIV-uninfected 
group as a control could potentially have helped to analyse the specific role of HIV infection in lipid disturbances. 
We did not include patients taking tenofovir alafenamide fumarate in the darunavir/cobicistat group, which 
would be desirable for a better analysis of the impact of tenofovir alafenamide fumarate on lipid disturbances.
In conclusion, we found no differences in the lipidomic profile, especially for ceramides, between patients 
treated with darunavir-based and those treated with an integrase inhibitor-based ART. To understand CV dis-
ease better in PLWH, especially the role of dyslipidaemia, further studies are needed to clarify the importance of 
multiple factors such as genetics, modifiable risk factors, diet, inflammation and senescence in addition to the 
role of ART exposure.
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